Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.34 USD | -0.74% | -14.67% | -30.01% |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Mar. 22 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Financials (USD)
Sales 2024 * | 50.25M | Sales 2025 * | 52.42M | Capitalization | 2.06B |
---|---|---|---|---|---|
Net income 2024 * | -512M | Net income 2025 * | -523M | EV / Sales 2024 * | 26.6 x |
Net cash position 2024 * | 717M | Net cash position 2025 * | 991M | EV / Sales 2025 * | 20.3 x |
P/E ratio 2024 * |
-3.85
x | P/E ratio 2025 * |
-4.02
x | Employees | 526 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.67% |
Latest transcript on Intellia Therapeutics, Inc.
1 day | -0.74% | ||
1 week | -14.67% | ||
Current month | -22.43% | ||
1 month | -22.03% | ||
3 months | -15.45% | ||
6 months | -23.68% | ||
Current year | -30.01% |
Managers | Title | Age | Since |
---|---|---|---|
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Glenn Goddard
DFI | Director of Finance/CFO | 53 | 18-10-28 |
Eliana Clark
CTO | Chief Tech/Sci/R&D Officer | 67 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Cohen
BRD | Director/Board Member | 67 | 19-01-23 |
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Frank Verwiel
CHM | Chairman | 62 | 17-07-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.15% | 2 M€ | -25.75% | ||
4.87% | 1 M€ | 0.00% | - | |
4.17% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 21.32 | -0.84% | 1,145,388 |
24-04-17 | 21.5 | -1.42% | 1,076,901 |
24-04-16 | 21.81 | -4.84% | 1,231,033 |
24-04-15 | 22.92 | -5.56% | 1,559,005 |
24-04-12 | 24.27 | -2.96% | 1,295,745 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.01% | 2.06B | |
-1.82% | 41.35B | |
+42.27% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- NTLA Stock